Zydus Cadila gets final approval from USFDA for Deferasirox Tablets

16 Jun 2020 Evaluate
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Deferasirox Tablets (US RLD: Jadenu Tablets) in the strengths of 90 mg, 180 mg and 360 mg. Deferasirox binds to iron and removes it from the bloodstream. It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old. It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old.

The drug will be manufactured at the group’s manufacturing facility at SEZ, Anmedabad. The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

965.00 17.10 (1.80%)
29-Apr-2024 11:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1523.65
Dr. Reddys Lab 6278.90
Cipla 1395.70
Zydus Lifesciences 965.00
Lupin 1641.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.